SEARCH

SEARCH BY CITATION

References

  • 1
    Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 2004;1:5970.
  • 2
    Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:354656.
  • 3
    Knobloch J, Sibbing B, Jungck D, Lin Y, Urban K, Stoelben E et al. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in COPD. J Pharmacol Exp Ther 2010;335:78898.
  • 4
    Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:2431.
  • 5
    Koch A, Giembycz M, Stirling RG, Lim S, Adcock I, Wassermann K et al. Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages. Eur Respir J 2004;23:80512.
  • 6
    Koch A, Giembycz M, Ito K, Lim S, Jazrawi E, Barnes PJ et al. Mitogen-activated protein kinase modulation of nuclear factor-kappaB-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. Am J Respir Cell Mol Biol 2004;30:3429.
  • 7
    Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:78696.
  • 8
    Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:190517.
  • 9
    Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:6417.
  • 10
    Suissa S, McGhan R, Niewoehner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:53542.
  • 11
    Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009;3:23543.
  • 12
    Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003;58:9426.
  • 13
    Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008;2:35174.
  • 14
    Wood LG, Wark PA, Garg ML. Antioxidant and anti-inflammatory effects of resveratrol in airway disease. Antioxid Redox Signal 2010;13:153548.
  • 15
    Knobloch J, Schild K, Jungck D, Urban K, Müller K, Schweda EK et al. The T-Helper Cell Type 1-Immune Response to Gram-Negative Bacterial Infections is Impaired in COPD. Am J Respir Crit Care Med 2011;183:20414.
  • 16
    Knobloch J, Peters H, Jungck D, Müller K, Strauch J, Koch A. TNFalpha-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. Thorax 2009;64:104452.
  • 17
    Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:24551.
  • 18
    Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26:6029.
  • 19
    Armstrong J, Sargent C, Singh D. Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin Exp Immunol 2009;158:7483.
  • 20
    Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009;11:285197.
  • 21
    Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010;54:716.